Researchers Identify Key Enzyme for Prostate Cancer Development

Researchers Identify Key Enzyme for Prostate Cancer Development
shutterstock_235472737A recent study published in The American Journal of Pathology by Thomas Jefferson University researchers has shown that the absence of a specific sirtuin enzyme, SIRT1, can result in the formation of early prostate cancer in animal models of the disease. Sirtuin enzymes are a class of proteins endowed with deacylase activity, and have been linked with several types of malignancies including neurodegeneration, obesity, heart disease, and cancer. "Using genetic deletion we found that SIRT1 normally restrains prostatic intraepithelial neoplasia in animals. Therefore too little SIRT1 may be involved in the cellular processes that starts human prostate cancer," study author Dr. Richard Pestell, M.D., Ph.D., MBA, executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center, said in a news release. "As we had shown that gene therapy based re expression of SIRT1 can block human prostate cancer tumor growth, and SIRT1 is an enzyme which can be targeted, this may be an important new target for prostate cancer prevention." In their study, titled “Loss of Sirt1
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *